Management of Cutaneous Dermatomyositis With Systemic Biologic Therapies: A Systematic Review.
作者信息
Sood Siddhartha, Akuffo-Addo Edgar, Abduelmula Abrahim, Heung Martin, Croitoru David O, Piguet Vincent
机构信息
Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
出版信息
J Cutan Med Surg. 2024 Sep-Oct;28(5):490-491. doi: 10.1177/12034754241265717. Epub 2024 Jul 26.
Abstract
摘要
相似文献
1
Management of Cutaneous Dermatomyositis With Systemic Biologic Therapies: A Systematic Review.系统性生物疗法治疗皮肤型皮肌炎的系统评价
J Cutan Med Surg. 2024 Sep-Oct;28(5):490-491. doi: 10.1177/12034754241265717. Epub 2024 Jul 26.
2
Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.难治性幼年皮肌炎的生物疗法：北美儿童关节炎与风湿病研究联盟的五年经验
Pediatr Rheumatol Online J. 2017 Jun 13;15(1):50. doi: 10.1186/s12969-017-0174-0.
3
Management of cutaneous dermatomyositis: current therapeutic options.皮肤型皮肌炎的管理：当前的治疗选择
Am J Clin Dermatol. 2006;7(6):341-51. doi: 10.2165/00128071-200607060-00002.
4
Advancements in the Treatment of Cutaneous Lupus Erythematosus and Dermatomyositis: A Review of the Literature.皮肤红斑狼疮和皮肌炎治疗的进展：文献综述
Clin Cosmet Investig Dermatol. 2022 Sep 8;15:1815-1831. doi: 10.2147/CCID.S382628. eCollection 2022.
5
Treatment escalation patterns to start biologics in refractory moderate juvenile dermatomyositis among members of the Childhood Arthritis and Rheumatology Research Alliance.难治性中度幼年特发性关节炎患儿中生物制剂起始治疗升级模式：儿童关节炎和风湿病研究联盟研究。
Pediatr Rheumatol Online J. 2023 Jan 6;21(1):3. doi: 10.1186/s12969-022-00785-5.
6
Emerging therapeutics in the management of connective tissue disease. Part II: Dermatomyositis and scleroderma.结缔组织病治疗新进展。第二部分：皮肌炎和硬皮病。
J Am Acad Dermatol. 2022 Jul;87(1):21-38. doi: 10.1016/j.jaad.2021.12.068. Epub 2022 Feb 22.
7
Pharmacological management of dermatomyositis.皮肌炎的药物治疗
Expert Rev Clin Pharmacol. 2017 Oct;10(10):1109-1118. doi: 10.1080/17512433.2017.1353910. Epub 2017 Jul 17.
8
Biologic drugs in the treatment of juvenile dermatomyositis: a literature review.生物制剂治疗幼年皮肌炎：文献综述。
Clin Rheumatol. 2024 Feb;43(2):591-602. doi: 10.1007/s10067-023-06740-3. Epub 2023 Aug 16.
9
Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: A systematic review.MDA-5 抗体阳性的临床无肌病性皮肌炎相关间质性肺病的治疗：系统评价。
Semin Arthritis Rheum. 2022 Apr;53:151959. doi: 10.1016/j.semarthrit.2022.151959. Epub 2022 Jan 31.
10
Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature.系统性硬皮病和皮肌炎皮肤钙沉着症的治疗：文献复习。
J Am Acad Dermatol. 2020 Feb;82(2):317-325. doi: 10.1016/j.jaad.2019.07.006. Epub 2019 Jul 11.
本文引用的文献
1
British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy.英国风湿病学会关于儿童、青少年及成人特发性炎性肌病管理的指南。
Rheumatology (Oxford). 2022 May 5;61(5):1760-1768. doi: 10.1093/rheumatology/keac115.
2
Myeloid Dendritic Cells Are Major Producers of IFN-β in Dermatomyositis and May Contribute to Hydroxychloroquine Refractoriness.髓系树突状细胞是皮肌炎中 IFN-β的主要产生者，可能导致羟氯喹耐药。
J Invest Dermatol. 2021 Aug;141(8):1906-1914.e2. doi: 10.1016/j.jid.2020.12.032. Epub 2021 Mar 4.
3
Update on outcome assessment in myositis.肌炎结局评估的最新进展。
Nat Rev Rheumatol. 2018 May;14(5):303-318. doi: 10.1038/nrrheum.2018.33. Epub 2018 Apr 12.
4
Architectural B-cell organization in skeletal muscle identifies subtypes of dermatomyositis.骨骼肌中的B细胞结构组织可识别皮肌炎的亚型。
Neurol Neuroimmunol Neuroinflamm. 2018 Mar 6;5(3):e451. doi: 10.1212/NXI.0000000000000451. eCollection 2018 May.
5
The pathogenesis of dermatomyositis.皮肌炎的发病机制。
Br J Dermatol. 2018 Dec;179(6):1256-1262. doi: 10.1111/bjd.15607. Epub 2017 May 24.
Zotero 插件